Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses.
BI 754091
BI 754111
LAG-3
PD-1
ezabenlimab
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
29
6
2022
Statut:
epublish
Résumé
Upregulation of inhibitory receptors, such as lymphocyte activation gene-3 (LAG-3), may limit the antitumor activity of therapeutic antibodies targeting the programmed cell death protein-1 (PD-1) pathway. We describe the binding properties of ezabenlimab, an anti-human PD-1 antibody, and BI 754111, an anti-human LAG-3 antibody, and assess their activity alone and in combination. Ezabenlimab bound with high affinity to human PD-1 (K
Identifiants
pubmed: 35756842
doi: 10.1080/2162402X.2022.2080328
pii: 2080328
pmc: PMC9225207
doi:
Substances chimiques
Antibodies, Blocking
0
Antibodies, Monoclonal
0
B7-H1 Antigen
0
Immune Checkpoint Inhibitors
0
Ligands
0
Programmed Cell Death 1 Receptor
0
Interferon-gamma
82115-62-6
Banques de données
ClinicalTrials.gov
['NCT03156114', 'NCT03433898']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2080328Informations de copyright
© 2022 Boehringer Ingelheim RCV GmbH & Co KG. Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the authors.
Références
Mol Cancer Ther. 2019 Nov;18(11):2051-2062
pubmed: 31395688
Immunity. 1999 Aug;11(2):141-51
pubmed: 10485649
Eur J Immunol. 1991 May;21(5):1229-33
pubmed: 1645269
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
Cancer Med. 2013 Oct;2(5):662-73
pubmed: 24403232
Cancer Immunol Res. 2015 Apr;3(4):412-23
pubmed: 25691328
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Cancer Res. 2003 Oct 1;63(19):6501-5
pubmed: 14559843
Cancer Res. 2012 Feb 15;72(4):917-27
pubmed: 22186141
Mol Cancer Ther. 2019 Mar;18(3):632-641
pubmed: 30587557
J Biol Chem. 2015 Feb 27;290(9):5462-9
pubmed: 25568323
Int Immunol. 2005 Feb;17(2):133-44
pubmed: 15611321
Nat Commun. 2017 Oct 26;8(1):1136
pubmed: 29070816
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32929051
MAbs. 2020 Jan-Dec;12(1):1685350
pubmed: 31856660
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Cancer Res. 2014 Jul 1;74(13):3418-28
pubmed: 24769443
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Oncoimmunology. 2020 Mar 12;9(1):1736792
pubmed: 32850194
Cancer Res. 2005 Feb 1;65(3):1089-96
pubmed: 15705911
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
J Immunol. 2002 Nov 15;169(10):5392-5
pubmed: 12421911
Nat Immunol. 2019 Sep;20(9):1129-1137
pubmed: 31358998
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Eur J Immunol. 2002 Aug;32(8):2255-63
pubmed: 12209638
Cell. 2019 Jan 10;176(1-2):334-347.e12
pubmed: 30580966
Oncoimmunology. 2016 Oct 28;6(1):e1249561
pubmed: 28197366